dabigatran is evaluated for the following indications with varying evidence strength: Non-valvular atrial fibrillation (evidence tier A), Venous thromboembolism (evidence tier A), Anticoagulation for mechanical heart valve (evidence tier F). See the full indication matrix with dosing and citations above on this page.

Q: What are the side effects of dabigatran?

Common side effects of dabigatran (≥ 1 in 100): Dyspepsia, gastritis-like symptoms (higher with dabigatran than other DOACs – linked to tartaric acid in the capsule), GI bleeding, Epistaxis, bruising, Anemia. See the Safety section for uncommon and serious reactions.

Q: Is dabigatran safe during pregnancy?

FDA category C. FDA category C. Pregnancy data are limited. When anticoagulation is indicated (VTE, AF) during pregnancy, low-molecular-weight heparins are preferred: they do not cross the placenta and have a larger clinical record. Dabigatran is used only when alternatives are unavailable.

Q: Is dabigatran compatible with breastfeeding?

Human breast milk data on dabigatran are absent. During lactation, anticoagulation is switched to warfarin or LMWH when therapy is required.

Q: Who should not take dabigatran?

dabigatran is contraindicated in: Active clinically significant bleeding; Lesions with high bleeding risk (GI ulcer, recent intracranial hemorrhage, esophageal varices); eGFR below 30 mL/min/1.73 m²; Mechanical heart valve prosthesis; Severe hepatic impairment. Full list in the Safety section.

Q: Does dabigatran carry an FDA boxed warning?

FDA boxed warning: premature discontinuation of dabigatran increases the risk of thrombotic events. Planned discontinuation requires transition to another anticoagulant if the indication remains. Spinal and epidural hematomas are possible in patients with neuraxial anesthesia or spinal puncture – prolonged monitoring and individualized timing between procedure and dosing are required.

Tromboembolismo venoso

Primera línea

Dabigatran is used for treatment of deep vein thrombosis and pulmonary embolism and for recurrence prevention. A specific feature of the dabigatran and edoxaban regimens: first 5–10 days of parenteral anticoagulation (LMWH), then a switch to dabigatran 150 mg twice daily. CHEST 2022 lists DOACs as first-line therapy for most VTE patients; warfarin is reserved for antiphospholipid syndrome, severe renal impairment, and active cancer (where direct factor Xa inhibitors are preferred).

Sources

Notas prácticas

Cuándo y cómo tomar

Taken twice daily 12 hours apart with or without food. Swallow the capsule whole – do not break or open it: removing the shell raises active-drug bioavailability and may increase bleeding risk by up to 75 percent. Keep the drug in the original blister pack: dabigatran is moisture-sensitive and loses activity if transferred to a pill organizer.

Titulación de dosis

Dose is not titrated by effect, it is selected upfront: 150 mg twice daily in AF with CHA2DS2-VA ≥ 2 in patients under 80 with eGFR above 50 mL/min/1.73 m²; 110 mg twice daily in patients over 80, with concomitant verapamil, with eGFR 30–50 mL/min/1.73 m², or with ≥ 3. In VTE always 150 mg twice daily after 5–10 days of parenteral therapy.

Monitorización

Routine INR, PT, and aPTT monitoring is not required. Before initiation check eGFR, hemoglobin, platelets, and liver enzymes. Repeat eGFR at 6 months, then yearly in stable patients and every 3 months at eGFR below 60 mL/min/1.73 m². In emergencies, dabigatran activity is measured with diluted thrombin time (dTT) or ecarin clotting time; aPTT gives only a rough estimate (a normal aPTT does not exclude therapeutic concentration).

Situaciones especiales

For elective surgery with low bleeding risk, hold for 24 hours (eGFR above 80), 36 hours (eGFR 50–80), 48–72 hours (eGFR below 50). For high bleeding risk, double the intervals. Restart 24–48 hours after stable hemostasis. In life-threatening bleeding, give idarucizumab 5 g intravenously – hemostasis is restored in minutes. St. John's Wort induces P-glycoprotein and reduces dabigatran concentration by 20–30 percent: patients are instructed to avoid it.

Mitos frecuentes

Myth: “DOACs have no antidote”. Fact: idarucizumab is a specific antidote to dabigatran, approved by and and available in Russia. Andexanet alfa is an antidote to direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

Myth: “dabigatran does not need INR monitoring – so no need to see the doctor”. Fact: INR is not needed, but assessment and renal function checks every 3–12 months are mandatory. A drop in eGFR below 30 mL/min/1.73 m² requires immediate discontinuation and a switch.

Myth: “the capsule can be opened and mixed with food for a child or older patient”. Fact: breaking the capsule shell raises bioavailability by 75 percent and increases bleeding risk. Dabigatran is taken whole.

De la ficha técnica

Importante

Resumen breve de la ficha técnica oficial. No sustituye el texto completo ni la consulta médica. Ficha del 28/02/2026. Fuente: AEMPS.

Indicaciones

Prevención primaria de episodios tromboembólicos venosos (TEV) en pacientes adultos sometidos a cirugía de reemplazo total de cadera o cirugía de reemplazo total de rodilla, programada en ambos casos. Prevención del ictus y de la embolia sistémica en pacientes adultos con fibrilación auricular no valvular (FANV), con uno o más factores de riesgo tales como ictus o ataque isquémico transitorio (AIT) previos; edad ≥75 años; insuficiencia ca rdíaca (≥ clase II en la escala NYHA); diabetes mellitus; hipertensión. Tratamiento de la trombosis venosa profunda (TVP) y de la embolia pulmonar (EP), y prevención de las recurrencias de la TVP y de la EP en adultos. Tratamiento del TEV y prevención del TEV recurrente en pacientes pediátricos desde el nacimiento hasta menos de 18 años de edad. Para las formas farmacéuticas apropiadas según la edad, ver sección 4.2 .

Contraindicaciones

Hipersensibilidad al principio activo o a alguno de los excipientes incluidos en la sección 6.1 Insuficiencia renal grave (ACr < 30 ml/min) en pacientes adultos TFGe < 50 ml/min/1,73 m 2 en pacientes pediátricos Hemorragia activa clínicamente significativa Lesiones o enfermedades, si se consideran un factor de riesgo significativo de sangrado mayor . Esto puede incluir úlcera gastrointestinal activa o reciente, presencia de neoplasias malignas con alto riesgo de sangrado, traumatismo cerebral o espinal reciente, cirugía cerebral, espinal u oftálmica reciente, hemorragia intracraneal reciente, conocimiento o sospecha de varices esofágicas, malformaciones arteriovenosas, aneurismas vasculares o anomalías vasculares intraespinales o intracerebrales mayores . Tratamiento concomitante con cualquier otro anticoagulante, p. ej., heparina no fraccionada (HNF), heparinas de bajo peso molecular (enoxaparina, dalteparina, etc.), derivados de la heparina (fondaparinux, etc.), anticoagulantes…

Dosis para adultos

Posología Dabigatrán etexilato cápsulas se puede usar en adultos y pacientes pediátricos de 8 años de edad o mayores que sean capaces de tragar las cápsulas enteras . Al cambiar entre las formulaciones puede ser necesario modificar la dosis prescrita. Se debe prescribir la dosis indicada en la tabla de posología pertinente de una formulación para la edad y el peso del niño . Prevención primaria del Tromboembolismo Venoso en cirugía ortopédica Las dosis recomendadas de dabigatrán etexilato y la duración del tratamiento para la prevención primaria del tromboembolismo venoso en cirugía ortopédica se muestran en la tabla 1. Tabla 1. Recomendaciones posológicas y duración del tratamiento para la prevención primaria del tromboembolismo venoso en cirugía ortopédica Inicio del tratamiento el día de la intervención quirúrgica 1-4 horas después de la finalización de la intervención Inicio de la dosis de mantenimiento el primer día después de la intervención quirúrgica Duración de la dosis de mantenimiento Pacientes tras una artroplastia de rodilla programada una única cápsula de 110 mg de dabigatrán etexilato 220 mg de dabigatrán etexilato una vez al día, administrados en 2 cápsulas de 110 mg 10 días Pacientes tras una artroplastia de cadera programada 28-35 días Reducción posológica recomendada Pacientes con insuficiencia renal moderada (aclaramiento de creatinina, ACr 30-50 ml/min ) una única cápsula de 75 mg de dabigatrán etexilato 150 mg de dabigatrán etexilato una vez al día,…

Preguntas frecuentes

What is dabigatran used for?

dabigatran is evaluated for the following indications with varying evidence strength: Non-valvular atrial fibrillation (evidence tier A), Venous thromboembolism (evidence tier A), Anticoagulation for mechanical heart valve (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of dabigatran?

Common side effects of dabigatran (≥ 1 in 100): Dyspepsia, gastritis-like symptoms (higher with dabigatran than other DOACs – linked to tartaric acid in the capsule), GI bleeding, Epistaxis, bruising, Anemia. See the Safety section for uncommon and serious reactions.

Is dabigatran safe during pregnancy?

FDA category C. FDA category C. Pregnancy data are limited. When anticoagulation is indicated (VTE, AF) during pregnancy, low-molecular-weight heparins are preferred: they do not cross the placenta and have a larger clinical record. Dabigatran is used only when alternatives are unavailable.

Is dabigatran compatible with breastfeeding?

Human breast milk data on dabigatran are absent. During lactation, anticoagulation is switched to warfarin or LMWH when therapy is required.

Who should not take dabigatran?

dabigatran is contraindicated in: Active clinically significant bleeding; Lesions with high bleeding risk (GI ulcer, recent intracranial hemorrhage, esophageal varices); eGFR below 30 mL/min/1.73 m²; Mechanical heart valve prosthesis; Severe hepatic impairment. Full list in the Safety section.

Does dabigatran carry an FDA boxed warning?

FDA boxed warning: premature discontinuation of dabigatran increases the risk of thrombotic events. Planned discontinuation requires transition to another anticoagulant if the indication remains. Spinal and epidural hematomas are possible in patients with neuraxial anesthesia or spinal puncture – prolonged monitoring and individualized timing between procedure and dosing are required.

“DOACs have no antidote”

idarucizumab is a specific antidote to dabigatran, approved by FDA and EMA and available in Russia. Andexanet alfa is an antidote to direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

“dabigatran does not need INR monitoring – so no need to see the doctor”

INR is not needed, but assessment and renal function checks every 3–12 months are mandatory. A drop in eGFR below 30 mL/min/1.73 m² requires immediate discontinuation and a switch.

“the capsule can be opened and mixed with food for a child or older patient”

breaking the capsule shell raises bioavailability by 75 percent and increases bleeding risk. Dabigatran is taken whole.

dabigatran

Mecanismo de acción

Indicaciones

Non-valvular atrial fibrillation

Tromboembolismo venoso

Anticoagulation for mechanical heart valve

Notas prácticas

Cuándo y cómo tomar

Titulación de dosis

Monitorización

Situaciones especiales

Mitos frecuentes

Interacciones con nutrientes

St. John's Wort

Interacciones farmacológicas

dronedarone

De la ficha técnica

Indicaciones

Contraindicaciones

Dosis para adultos

Seguridad

Contraindicaciones

Reacciones adversas graves

Reacciones adversas frecuentes

Reacciones adversas poco frecuentes

EmbarazoFDA C

Lactancia

Preguntas frecuentes